Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:acquisition |
Acquired by a private equity firm in 2021
|
| gptkbp:awards |
Best Places to Work 2020
Top 10 Biotech Companies 2021 |
| gptkbp:ceo |
gptkb:Mark_Enyedy
|
| gptkbp:clinical_trial |
combination therapies
biomarker studies investigational new drug applications safety and efficacy studies Phase 1 trials for IMG N632 Phase 1/2 trials for new drugs Phase 2 trials for various therapies Phase 3 trials for Mirvetuximab soravtansine ongoing trials for various cancers |
| gptkbp:collaborations |
collaborative research with academic institutions
|
| gptkbp:community_engagement |
active in community outreach programs
|
| gptkbp:employees |
approximately 200
|
| gptkbp:financial_products |
gptkb:Company
|
| gptkbp:focus |
cancer therapeutics
|
| gptkbp:founded |
gptkb:1981
|
| gptkbp:headcount |
200 employees
|
| gptkbp:headquarters |
gptkb:Waltham,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immuno Gen, Inc.
|
| gptkbp:invention |
multiple patents in antibody-drug conjugates
|
| gptkbp:investment |
Institutional investors
significant investments in R& D |
| gptkbp:leadership |
diverse leadership team
|
| gptkbp:market_cap |
$1 billion (2023)
|
| gptkbp:net_worth |
-$30 million (2022)
|
| gptkbp:partnerships |
gptkb:temple
gptkb:Bristol-Myers_Squibb collaboration with Merck collaboration with Roche |
| gptkbp:products |
gptkb:Mirvetuximab_soravtansine
IMG N632 |
| gptkbp:receives_funding_from |
government grants
funded by venture capital |
| gptkbp:research_and_development |
antibody-drug conjugates
|
| gptkbp:research_focus |
gptkb:healthcare_organization
ovarian cancer immuno-oncology targeted cancer therapies novel therapeutic approaches |
| gptkbp:revenue |
$50 million (2022)
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:strategic_importance |
enhance shareholder value
expand product pipeline increase market presence |
| gptkbp:subsidiary |
gptkb:Immuno_Gen_Europe_Ltd.
|
| gptkbp:symbol |
IMGN
|
| gptkbp:technology |
targeted delivery systems
proprietary linker technology |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.immunogen.com
|